Multinational biotechnology firm Biogen has confirmed it’s going to shut down Biogen Digital Well being, a world unit of the biotech firm, and pullout of a examine with Apple. Nonetheless, the corporate says it’s going to proceed to combine some digital capabilities into different capabilities of its enterprise.
“As our CEO Chris Viehbacher talked about when he introduced Match for Development, a part of the initiative is eradicating layers within the group, turning into much less complicated and extra agile, and making strategic investments in inner and exterior innovation. Consequently, some capabilities are evolving their working fashions,” a Biogen spokesperson informed MobiHealthNews in an e-mail.
Biogen Digital Well being was launched in 2021 and employs round 150 individuals with places in Boston, Zurich and Paris. The corporate focuses on merging biology and know-how to enhance neurology, immunology and psychological well being care.
The biotech big stated digital medication and well being applied sciences will stay an important a part of its plan to derisk and speed up its analysis and growth engine and industrial operations.
“Biogen Digital Well being is evolving. We’re presently assessing our digital technique and potential future investments within the house, and we will probably be integrating sure digital capabilities from BDH into related capabilities. We are going to proceed to advance quite a few efforts, reminiscent of growth of digital biomarkers for Parkinson’s and early AD [Alzheimer’s disease], in addition to our digital options for uncommon illnesses. Going ahead, we’ll leverage exterior capabilities and partnerships to seize advances within the area which can be intently linked to our evolving R&D and industrial priorities and areas of focus,” the spokesperson stated.
In 2021, the corporate started a examine with Apple to research iPhone and Apple Watch sensor knowledge and metrics to distinguish people with regular cognition from these with delicate cognitive impairment to create a cognitive wellness rating that follows shifts in cognitive efficiency over time.
“Relating to the Instinct examine with Apple, although it has been discontinued resulting from Biogen’s R&D prioritization efforts, due to the higher-than-expected stage of engagement of individuals, the examine stays properly positioned to handle its major aims. Preliminary outcomes assist the feasibility, acceptability and functionality to achieve underserved and underrepresented populations and to reliably measure cognition and habits in real-world unsupervised settings. Further insights from the Research will probably be printed at a later time,” Biogen informed MobiHealthNews.
THE LARGER TREND
Biogen introduced it accomplished its acquisition of California-based pharma firm Reata earlier this week for a reported $7.3 billion. The acquisition provides SKYCLARYS to the corporate’s uncommon illness portfolio, the one FDA-approved remedy for Friedreich’s ataxia within the U.S.